Report Detail
COVID-19 Impact on Global Cancer Immunotherapies Market Insights, Forecast to 2026
- RnM4063966 |
- 16 June, 2020 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
Cancer Immunotherapies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Immunotherapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cancer Immunotherapies market is segmented into
Monoclonal Antibodies (MABs)
Cancer Vaccines
Immunomodulators
Adoptive Cell transfer
Checkpoint Inhibitors
Segment by Application, the Cancer Immunotherapies market is segmented into
Breast Cancer
Leukemia
Lymphoma
Melanoma
Colorectal Cancer
Non-Small Cell Lung Cancer
Regional and Country-level Analysis
The Cancer Immunotherapies market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cancer Immunotherapies market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cancer Immunotherapies Market Share Analysis
Cancer Immunotherapies market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Immunotherapies business, the date to enter into the Cancer Immunotherapies market, Cancer Immunotherapies product introduction, recent developments, etc.
The major vendors covered:
Amgen
AstraZeneca
Roche
Bristol-Myers Squibb
Bayer
Merck
ARMO BioSciences (Eli Lilly)
Novartis
Pfizer
Johnson & Johnson
AbbVie
Gilead Sciences
1 Study Coverage
- 1.1 Cancer Immunotherapies Product Introduction
- 1.2 Market Segments
- 1.3 Key Cancer Immunotherapies Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Cancer Immunotherapies Market Size Growth Rate by Type
- 1.4.2 Monoclonal Antibodies (MABs)
- 1.4.3 Cancer Vaccines
- 1.4.4 Immunomodulators
- 1.4.5 Adoptive Cell transfer
- 1.4.6 Checkpoint Inhibitors
- 1.5 Market by Application
- 1.5.1 Global Cancer Immunotherapies Market Size Growth Rate by Application
- 1.5.2 Breast Cancer
- 1.5.3 Leukemia
- 1.5.4 Lymphoma
- 1.5.5 Melanoma
- 1.5.6 Colorectal Cancer
- 1.5.7 Non-Small Cell Lung Cancer
- 1.6 Coronavirus Disease 2019 (Covid-19): Cancer Immunotherapies Industry Impact
- 1.6.1 How the Covid-19 is Affecting the Cancer Immunotherapies Industry
- 1.6.1.1 Cancer Immunotherapies Business Impact Assessment - Covid-19
- 1.6.1.2 Supply Chain Challenges
- 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
- 1.6.2 Market Trends and Cancer Immunotherapies Potential Opportunities in the COVID-19 Landscape
- 1.6.3 Measures / Proposal against Covid-19
- 1.6.3.1 Government Measures to Combat Covid-19 Impact
- 1.6.3.2 Proposal for Cancer Immunotherapies Players to Combat Covid-19 Impact
- 1.6.1 How the Covid-19 is Affecting the Cancer Immunotherapies Industry
- 1.7 Study Objectives
- 1.8 Years Considered
2 Executive Summary
- 2.1 Global Cancer Immunotherapies Market Size Estimates and Forecasts
- 2.1.1 Global Cancer Immunotherapies Revenue 2015-2026
- 2.1.2 Global Cancer Immunotherapies Sales 2015-2026
- 2.2 Cancer Immunotherapies Market Size by Region: 2020 Versus 2026
- 2.2.1 Global Cancer Immunotherapies Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.2.2 Global Cancer Immunotherapies Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cancer Immunotherapies Competitor Landscape by Players
- 3.1 Cancer Immunotherapies Sales by Manufacturers
- 3.1.1 Cancer Immunotherapies Sales by Manufacturers (2015-2020)
- 3.1.2 Cancer Immunotherapies Sales Market Share by Manufacturers (2015-2020)
- 3.2 Cancer Immunotherapies Revenue by Manufacturers
- 3.2.1 Cancer Immunotherapies Revenue by Manufacturers (2015-2020)
- 3.2.2 Cancer Immunotherapies Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Cancer Immunotherapies Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Cancer Immunotherapies Revenue in 2019
- 3.2.5 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Cancer Immunotherapies Price by Manufacturers
- 3.4 Cancer Immunotherapies Manufacturing Base Distribution, Product Types
- 3.4.1 Cancer Immunotherapies Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Cancer Immunotherapies Product Type
- 3.4.3 Date of International Manufacturers Enter into Cancer Immunotherapies Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
- 4.1 Global Cancer Immunotherapies Market Size by Type (2015-2020)
- 4.1.1 Global Cancer Immunotherapies Sales by Type (2015-2020)
- 4.1.2 Global Cancer Immunotherapies Revenue by Type (2015-2020)
- 4.1.3 Cancer Immunotherapies Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Cancer Immunotherapies Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Cancer Immunotherapies Sales Forecast by Type (2021-2026)
- 4.2.2 Global Cancer Immunotherapies Revenue Forecast by Type (2021-2026)
- 4.2.3 Cancer Immunotherapies Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Cancer Immunotherapies Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Breakdown Data by Application (2015-2026)
- 5.1 Global Cancer Immunotherapies Market Size by Application (2015-2020)
- 5.1.1 Global Cancer Immunotherapies Sales by Application (2015-2020)
- 5.1.2 Global Cancer Immunotherapies Revenue by Application (2015-2020)
- 5.1.3 Cancer Immunotherapies Price by Application (2015-2020)
- 5.2 Cancer Immunotherapies Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Cancer Immunotherapies Sales Forecast by Application (2021-2026)
- 5.2.2 Global Cancer Immunotherapies Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Cancer Immunotherapies Price Forecast by Application (2021-2026)
6 North America
- 6.1 North America Cancer Immunotherapies by Country
- 6.1.1 North America Cancer Immunotherapies Sales by Country
- 6.1.2 North America Cancer Immunotherapies Revenue by Country
- 6.1.3 U.S.
- 6.1.4 Canada
- 6.2 North America Cancer Immunotherapies Market Facts & Figures by Type
- 6.3 North America Cancer Immunotherapies Market Facts & Figures by Application
7 Europe
- 7.1 Europe Cancer Immunotherapies by Country
- 7.1.1 Europe Cancer Immunotherapies Sales by Country
- 7.1.2 Europe Cancer Immunotherapies Revenue by Country
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 U.K.
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Cancer Immunotherapies Market Facts & Figures by Type
- 7.3 Europe Cancer Immunotherapies Market Facts & Figures by Application
8 Asia Pacific
- 8.1 Asia Pacific Cancer Immunotherapies by Region
- 8.1.1 Asia Pacific Cancer Immunotherapies Sales by Region
- 8.1.2 Asia Pacific Cancer Immunotherapies Revenue by Region
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam
- 8.2 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Type
- 8.3 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Application
9 Latin America
- 9.1 Latin America Cancer Immunotherapies by Country
- 9.1.1 Latin America Cancer Immunotherapies Sales by Country
- 9.1.2 Latin America Cancer Immunotherapies Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina
- 9.2 Central & South America Cancer Immunotherapies Market Facts & Figures by Type
- 9.3 Central & South America Cancer Immunotherapies Market Facts & Figures by Application
10 Middle East and Africa
- 10.1 Middle East and Africa Cancer Immunotherapies by Country
- 10.1.1 Middle East and Africa Cancer Immunotherapies Sales by Country
- 10.1.2 Middle East and Africa Cancer Immunotherapies Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E
- 10.2 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Type
- 10.3 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Application
11 Company Profiles
- 11.1 Amgen
- 11.1.1 Amgen Corporation Information
- 11.1.2 Amgen Description, Business Overview and Total Revenue
- 11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Amgen Cancer Immunotherapies Products Offered
- 11.1.5 Amgen Recent Development
- 11.2 AstraZeneca
- 11.2.1 AstraZeneca Corporation Information
- 11.2.2 AstraZeneca Description, Business Overview and Total Revenue
- 11.2.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
- 11.2.4 AstraZeneca Cancer Immunotherapies Products Offered
- 11.2.5 AstraZeneca Recent Development
- 11.3 Roche
- 11.3.1 Roche Corporation Information
- 11.3.2 Roche Description, Business Overview and Total Revenue
- 11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
- 11.3.4 Roche Cancer Immunotherapies Products Offered
- 11.3.5 Roche Recent Development
- 11.4 Bristol-Myers Squibb
- 11.4.1 Bristol-Myers Squibb Corporation Information
- 11.4.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
- 11.4.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
- 11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Products Offered
- 11.4.5 Bristol-Myers Squibb Recent Development
- 11.5 Bayer
- 11.5.1 Bayer Corporation Information
- 11.5.2 Bayer Description, Business Overview and Total Revenue
- 11.5.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
- 11.5.4 Bayer Cancer Immunotherapies Products Offered
- 11.5.5 Bayer Recent Development
- 11.6 Merck
- 11.6.1 Merck Corporation Information
- 11.6.2 Merck Description, Business Overview and Total Revenue
- 11.6.3 Merck Sales, Revenue and Gross Margin (2015-2020)
- 11.6.4 Merck Cancer Immunotherapies Products Offered
- 11.6.5 Merck Recent Development
- 11.7 ARMO BioSciences (Eli Lilly)
- 11.7.1 ARMO BioSciences (Eli Lilly) Corporation Information
- 11.7.2 ARMO BioSciences (Eli Lilly) Description, Business Overview and Total Revenue
- 11.7.3 ARMO BioSciences (Eli Lilly) Sales, Revenue and Gross Margin (2015-2020)
- 11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Products Offered
- 11.7.5 ARMO BioSciences (Eli Lilly) Recent Development
- 11.8 Novartis
- 11.8.1 Novartis Corporation Information
- 11.8.2 Novartis Description, Business Overview and Total Revenue
- 11.8.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
- 11.8.4 Novartis Cancer Immunotherapies Products Offered
- 11.8.5 Novartis Recent Development
- 11.9 Pfizer
- 11.9.1 Pfizer Corporation Information
- 11.9.2 Pfizer Description, Business Overview and Total Revenue
- 11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
- 11.9.4 Pfizer Cancer Immunotherapies Products Offered
- 11.9.5 Pfizer Recent Development
- 11.10 Johnson & Johnson
- 11.10.1 Johnson & Johnson Corporation Information
- 11.10.2 Johnson & Johnson Description, Business Overview and Total Revenue
- 11.10.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
- 11.10.4 Johnson & Johnson Cancer Immunotherapies Products Offered
- 11.10.5 Johnson & Johnson Recent Development
- 11.1 Amgen
- 11.1.1 Amgen Corporation Information
- 11.1.2 Amgen Description, Business Overview and Total Revenue
- 11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Amgen Cancer Immunotherapies Products Offered
- 11.1.5 Amgen Recent Development
- 11.12 Gilead Sciences
- 11.12.1 Gilead Sciences Corporation Information
- 11.12.2 Gilead Sciences Description, Business Overview and Total Revenue
- 11.12.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
- 11.12.4 Gilead Sciences Products Offered
- 11.12.5 Gilead Sciences Recent Development
12 Future Forecast by Regions (Countries) (2021-2026)
- 12.1 Cancer Immunotherapies Market Estimates and Projections by Region
- 12.1.1 Global Cancer Immunotherapies Sales Forecast by Regions 2021-2026
- 12.1.2 Global Cancer Immunotherapies Revenue Forecast by Regions 2021-2026
- 12.2 North America Cancer Immunotherapies Market Size Forecast (2021-2026)
- 12.2.1 North America: Cancer Immunotherapies Sales Forecast (2021-2026)
- 12.2.2 North America: Cancer Immunotherapies Revenue Forecast (2021-2026)
- 12.2.3 North America: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
- 12.3 Europe Cancer Immunotherapies Market Size Forecast (2021-2026)
- 12.3.1 Europe: Cancer Immunotherapies Sales Forecast (2021-2026)
- 12.3.2 Europe: Cancer Immunotherapies Revenue Forecast (2021-2026)
- 12.3.3 Europe: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
- 12.4 Asia Pacific Cancer Immunotherapies Market Size Forecast (2021-2026)
- 12.4.1 Asia Pacific: Cancer Immunotherapies Sales Forecast (2021-2026)
- 12.4.2 Asia Pacific: Cancer Immunotherapies Revenue Forecast (2021-2026)
- 12.4.3 Asia Pacific: Cancer Immunotherapies Market Size Forecast by Region (2021-2026)
- 12.5 Latin America Cancer Immunotherapies Market Size Forecast (2021-2026)
- 12.5.1 Latin America: Cancer Immunotherapies Sales Forecast (2021-2026)
- 12.5.2 Latin America: Cancer Immunotherapies Revenue Forecast (2021-2026)
- 12.5.3 Latin America: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
- 12.6 Middle East and Africa Cancer Immunotherapies Market Size Forecast (2021-2026)
- 12.6.1 Middle East and Africa: Cancer Immunotherapies Sales Forecast (2021-2026)
- 12.6.2 Middle East and Africa: Cancer Immunotherapies Revenue Forecast (2021-2026)
- 12.6.3 Middle East and Africa: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter’s Five Forces Analysis
- 13.5 Primary Interviews with Key Cancer Immunotherapies Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Cancer Immunotherapies Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
Summary:
Get latest Market Research Reports on COVID-19 Impact on Global Cancer Immunotherapies. Industry analysis & Market Report on COVID-19 Impact on Global Cancer Immunotherapies is a syndicated market report, published as COVID-19 Impact on Global Cancer Immunotherapies Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of COVID-19 Impact on Global Cancer Immunotherapies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
